Latest Investigation News

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

MRG Metals has verified substantial concentrations of valuable heavy minerals including monazite, rutile and zircon in alluvial deposits at its Adriano Rare Earth Project, with a total rare earth oxide content of 1.46%.

Galileo Mining’s latest diamond drilling at Norseman reveals a newly identified ultramafic sill with 109 metres of PGM mineralisation, reinforcing the project’s potential for multiple stacked intrusive systems along extensive strike lengths.

Tartana Minerals revises its corporate presentation to clarify prior disclosures while spotlighting a $4.5 million capital raise to boost copper sulphate production and expand drilling across its Far North Queensland portfolio.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Lotus Resources has disclosed operational challenges at its Kayelekera uranium mine, revising production figures downward and delaying steady-state output to the third quarter of 2026.

Australian Mines has reaffirmed strong economics for its Flemington Scandium Project, highlighting a robust 28-year mine life and significant leverage to scandium price scenarios.

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.

Ark Mines has intercepted low-grade gold in its Sandy Mitchell Rare Earths Project, revealing potential value-add from gold credits alongside rare earths. Further assays and development studies are underway.

CuFe’s expanded scoping study for its Orlando copper-gold project integrates underground mining and new bismuth and silver revenue streams, lifting project NPV to A$908 million at spot prices and shortening payback to 10 months.